Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: Time trends in a spanish multicenter study of 1000 patients

Journal of Clinical Gastroenterology

Volumn 47, Issue 2, 2013, Pages 130-135

  Gisbert, Javier P ^a   Pérez Aisa, Ángeles ^b   Bermejo, Fernando ^c   Castro Fernández, Manuel ^a   Almela, Pedro ^d   Barrio, Jesús ^e   Cosme, Ángel ^a   Modolell, Inés ^f   Bory, Felipe ^d   Fernández Bermejo, Miguel ^g   Rodrigo, Luis ^h   Ortuño, Jesús ^a   Sánchez Pobre, Pilar ⁱ   Khorrami, Sam ^j   Franco, Alejandro ^k   Tomas, Albert ^d   Guerra, Iván ^c   Lamas, Eloisa ^a   Ponce, Julio ^a   Calvet, Xavier ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d Gastroenterology Unit   (Spain)

^e Gastroenterology Unit   (Spain)

^f Brain   (Spain)

^g Gastroenterology Unit   (Spain)

^h Gastroenterology Unit   (Spain)

ⁱ Hospital Universitario del Sureste de Madrid   (Spain)

^j Palma de Mallorca   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

eradication; failure; Helicobacter pylori; levofloxacin; quinolones; rescue; therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ANOREXIA; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SPAIN; THRUSH; UREA BREATH TEST; VAGINA CANDIDIASIS; VOMITING;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFLOXACIN; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUESTIONNAIRES; REMISSION INDUCTION; SPAIN; TIME FACTORS; TREATMENT FAILURE;

EID: 84872958427     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318254ebdd     Document Type: Article

References (47)

1. Graham DY, Fischbach L. Helicobacter pylori infection. N Engl J Med. 2010;363:595-596; author reply 6.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781.
3. Gisbert JP, Calvet X. Review article: The effectiveness of standard triple-therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268.
4. O'Connor A, Gisbert JP, McNamara D, et al. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15(suppl 1): 46-52.
5. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384.
6. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-1057.
7. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385-5402.
8. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005;10:363-372.
9. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769-2802.
10. Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Ther Adv Gastroenterol. 2011;4:103-114.
11. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35-44.
12. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-496.
13. Li Y, Huang X, Yao L, et al. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413-422.
14. Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103:71-76.
15. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480-485.
16. Gisbert JP, Badia X, Roset M, et al. The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28-38.
17. Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283-285.
18. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39-45.
19. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis. 2003;35:711-715.
20. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22:45-49.
21. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004; 2:997-1002.
22. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821-825.
23. Cheng HC, Chang WL, Chen WY, et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter. 2007;12:359-363.
24. Gisbert JP, Gisbert JL, Marcos S, et al. Levofloxacin vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter. 2007;12:68-73.
25. Jung HS, Shim KN, Baik SJ, et al. Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol. 2008;51:285-290.
26. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother. 2009;63:1017-1024.
27. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter. 2006;11:418-424.
28. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol. 2006;48:19-24.
29. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010; 59:572-578.
30. Marzio L, Coraggio D, Capodicasa S, et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006;11:237-242.
31. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helico-bacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627-633.
32. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39:1001-1005.
33. Perri F, Festa V, Merla A, et al. Randomized study of different"second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther. 2003;18:815-820.
34. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for Helico-bacter pylori eradication. Neth J Med. 2009;67:96-101.
35. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:421-427.
36. Zullo A, De Francesco V, Manes G, et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointest Liver Dis. 2010;19:131-134.
37. Gisbert JP, Marcos S, Gisbert JL, et al. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol. 2001;13: 1303-1307.
38. de Boer WA, Tytgat GN. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol. 2001; 13:1281-1284.
39. Ercin CN, Uygun A, Toros AB, et al. Comparison of 7-and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol. 2010;21:12-16.
40. Madisch A, Hanel C, Morgner A, et al. Experience with high-dose and standard-dose levofloxacin-based therapy of Helico-bacter pylori infection with known antimicrobial susceptibility pattern. Gastroenterology. 2007;13(suppl 2):T2073.
41. Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;15:460-466.
42. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastro-intest Liver Dis. 2010;19:409-414.
43. Megraud F, Kist M, Lopez Brea M, et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009. Gastroenterology. 2011;140(suppl 1):1715.
44. Perez-Trallero E, Ramirez-Lazaro MJ, Villar H, et al. Resistencia de Helicobacter pylori a diversos antibioticos: un estudio multi-centrico espanol. Gastroenterol Hepatol. 2011;34:236.
45. Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med. 2011;50:2717.
46. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009; 104:21-25.
47. Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354.